RBMX and neoplasm: We also found that vemurafenib plus palbociclib maintained down-regulation of p-AKT (critical pro-survival factor) protein levels when RBMX (sh-RBMX) was silenced compared to the single agent or vehicle treatments (Figure 4B), suggesting that this combined therapeutic approach could have anti-tumor survival activity by affecting AKT expression levels and subsequently its downstream effectors.